
GDTC P/E Ratio
P/E Ratio as of Jun 13, 2025: -12.73
Average-13.31
Median-13.22
Minimum-14.57
Maximum-12.31
-12.73
Past Month+1.65 (11.47%)
The P/E ratio for GDTC is -12.73 as of Jun 13, 2025. This represents a increase of 10.89% compared to its 12-month average P/E ratio of -11.48. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Cytomed Therapeutics Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Cytomed Therapeutics Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Cytomed Therapeutics Ltd to industry peers.
Cytomed Therapeutics Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Cytomed Therapeutics Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Cytomed Therapeutics Ltd to industry peers.
GDTC P/E Ratio Insights
See Cytomed Therapeutics Ltd’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in GDTC
Order type
Buy in
Order amount
Est. shares
0 shares
GDTC P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $2.34 | -14.32 |
May 1, 2025 | $2.30 | -14.08 |
Apr 1, 2025 | $2.20 | -11.17 |
Mar 3, 2025 | $2.81 | -14.27 |
Feb 3, 2025 | $2.79 | -14.17 |
Jan 2, 2025 | $3.50 | -17.78 |
GDTC End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -12.73 | -26.29% |
2024 | -17.27 | -1.20% |
2023 | -17.48 | — |
FAQs About Cytomed Therapeutics Ltd (GDTC) P/E ratio
The latest P/E ratio of GDTC is -12.73, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Cytomed Therapeutics Ltd’s last 12-month average P/E ratio is -11.48, compared to its current P/E ratio of -12.73. This reflects a increase of 10.89%.
Cytomed Therapeutics Ltd’s current P/E ratio of -12.73 is higher than its last 12-month average P/E of -11.48. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Cytomed Therapeutics Ltd’s average P/E ratio over the last 3 years is -9.73. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Cytomed Therapeutics Ltd’s average P/E ratio over the last 5 years is -5.83. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.